Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

NCT02303730 on ClinicalTrials.gov · last registry update 2019-08-28

Finished November 2017, after enrolling 76 people. Primary outcome, as filed: Change in liver fat content（%） measured by MRS. exenatide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Fudan University
Sponsor type: Other
Enrollment: 76
Started: 2015-03
Primary completion: 2017-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in liver fat content（%） measured by MRS

Conditions studied

Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.